INN Working Document 25.619
12/06/2025

Addendum* to *"The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024"*

ISBN 9-789240-099388

Programme on International Nonproprietary Names (INN)

Health Products Policy and Standards (HPS)
Access to Medicines and Health Products (MHP)

World Health Organization, Geneva

Addendum* to "The use of stem s in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - ISBN 9-789240-099388

* This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of *"The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances"* 2024.

-alkib	**ALK (anaplastic lymphoma kinase) inhibitors** dirozalkib (132), envonalkib (126), ficonalkib (128), neladalkib (130), iruplinalkib (126), zotizalkib (128) under (c) category: alectinib (108), brigatinib (113), ceritinib (109), crizotinib (103), ensartinib (115), nasartinib (115)
-ampator	**α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators** farampator (92), mibampator (103), osavampator (129), pesampator (126), tulrampator (116)
-cirnon	**CC chemokine receptor (CCR) antagonists** ilacirnon (123), lazucirnon (123), tivumecirnon (128), vercirnon (107), zelnecirnon (130)
defer-/-defer-	**iron chelating agents** **deferitrin (or desferrithiocin) derivatives,** cideferron (39), deferiprone (67), deferitazole (108), deferitrin (92), petadeferitrin (132) **others**: deferoxamine (14)(!), deferasirox (86)
-menib	**menin interaction inhibitors** balomenib (132), bleximenib (129), emilumenib (129), enzomenib (130), icovamenib (130), revumenib (126), ziftomenib (127)
-nosine	**purine nucleoside analogues, antivirals or antineoplastics** adenosine phosphate (14), ateganosine (130), didanosine (64), fosdesdenosine sipalabenamide (130), inosine (42), lodenosine (78) (b) category: alanosine (48)
-protafib	**human protein tyrosine phosphatase (HPTP) inhibitors** batoprotafib (127), ertiprotafib (87), migoprotafib (128), osunprotafib (129), razuprotafib (116), tegeprotafib (129), vociprotafib (127)
-rogant	**retinoic acid receptor-related orphan receptor gamma (RORγ) antagonists and inverse agonists** bevurogant (125), cedirogant (123), izumerogant (128), retezorogant (126), vimirogant (120)
-stat ***-drostat***	enzyme inhibitors **inhibitors of the synthesis of aldosterone and cortisol** osilodrostat (110), baxdrostat (125), dexfadrostat (126), lorundrostat (127), vicadrostat (130)

-tide	peptides
-lintide	**amylin receptor agonists including dual amylin / calcitonin receptor agonists** amlintide (76), cagrilintide (123), colulintide (132), eloralintide (131), davalintide (101), petrelintide (129), pramlintide (74)
-votide	**PSMA (prostate-specific membrane antigen, glutamate carboxypeptidase 2)-binding peptides** actinium (^{225}Ac) zadavotide guraxetan (132), lutetium (^{177}Lu) tezuvotide tetraxetan (131), lutetium (^{177}Lu) vipivotide tetraxetan (123), lutetium (^{177}Lu) zadavotide guraxetan (125), sonzivotide filricianine (132), vipivotide tetraxetan (130), sonzivotide filricianine (132), vipivotide tetraxetan (130)
-tinib	tyrosine kinase inhibitors
-gratinib	**fibroblast growth factor receptors (FGFR) inhibitors** dabogratinib (132), fanregratinib (131), gunagratinib (125), infigratinib (112), ratangratinib (132), tasurgratinib (124), zoligratinib (122) **under (c) category**: futabatinib (119), pemigatinib (118), rogaratinib (115)
-turev	**under the advanced therapy scheme for: oncolytic viruses** canerpaturev (117), gebasaxturev (126), lerapolturev (125), linoserpaturev (131), suratadenoturev (123), tasadenoturev (117), teserpaturev (119) under (c) category: enadenotucirev (111)
-vatein	***protein vaccine substances***
-covatein	**coronavirus** carocovatein (128), enlicovatein (128), girocovatein (132), laricovatein (128), riticovatein (128), tibrecovatein (128) inter-related INN: -*alsecovatein* (128), miv*alsecovatein* (131), up*alsecovatein* (129) -selvacovatein (128), damlecovatein (131) -*sorimcovatein* (128), pe*sorimcovatein* (130), ti*sorimcovatein* (130)
-vir	antivirals
-trelvir	**antiviral 3CL protease inhibitors** abimtrelvir (126), atilotrelvir (129), bofutrelvir (127), deunirmatrelvir (129), ensitrelvir (126), ibuzatrelvir (129), imocitrelvir (130), iscartrelvir (130), limnetrelvir (130), lufotrelvir (125), nirmatrelvir (126), olgotrelvir (129), pomotrelvir (127), ratutrelvir (132), secutrelvir (132), zevotrelvir (129)

*****

*****

Changes were also made in the following stems' definitions:

-cianine
from *indocyanine fluorescence dye group*
to *cyanine dyes and their derivatives, diagnostic imaging agents*

-fylline
from *N-methylated xanthine derivatives*
to *N-**alkylated** xanthine derivatives*

-ilide
from *class III antiarrhythmics, sematilide derivatives*
to *class III antiarrhythmics, ~~sematilide derivatives~~*

-kalim
from *potassium channel activators, antihypertensives.*
to *potassium channel activators, ~~antihypertensives~~.*

-kinra
from *interleukin receptor antagonists and interleukin antagonists*
to *interleukin receptor antagonists and interleukin inhibitors*

-(o)nidine
from *antihypertensives, clonidine derivatives*
to *α_2 adrenoreceptor agonists*

under *-rsen*
-dirsen
from *targeting muscular dystrophies*
to *splice-switching oligonucleotides, muscular dystrophies*

under *-tant*
-netant
from *neurokinin NK3 receptor antagonists*
to *neurokinin NK3 and dual NK3-NK1 receptor antagonists*

-tirom(e) (future use of final (e) is discouraged to avoid conflict with -terone stem)
from *antihyperlipidemic, thyromimetic derivatives*
to *~~antihyperlipidemic~~, thyromimetic derivatives*

Changes were also made in the stem's infix:
-gromab (under -mab)
from *-gro**s**mab*
for the designation of INN for monoclonal antibodies targeting skeletal muscle mass related growth factors and receptors

***-ki-* (under *-mab*)**
from the designation of INN for monoclonal antibodies targeting interleukins,
to cytokine and cytokine receptors

Please note that a new naming scheme for monoclonal antibodies was adopted at the 73rd INN Consultation. The document can be retrieved here after and from our webpages at:
https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/new_mab_-nomenclature-_2021.pdf?sfvrsn=207e78cb_12&download=true